Merck reorganizing R&D by adding some jobs, cutting others

mer

Merck's big plans for its R&D efforts on both coasts mean it will close an operation in Pennsylvania, costing some jobs there and in New Jersey while adding jobs elsewhere.

The Kenilworth, NJ-based drugmaker today confirmed a report by the In The Pipeline blog about its plans. In an email, the company said Merck Research Laboratories intends to boost its investment in ”exploratory biology,” specifically in Cambridge, MA, and the San Francisco Bay area.

“Unfortunately, these changes will result in workforce reductions at our Kenilworth and Rahway, N.J. sites and our North Wales, Pa. screening facility as we shift resources and personnel," the company said.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Merck isn't providing any specific numbers on what the move will mean for jobs at each operation, but it anticipates that it'll affect less than 10% of discovery, preclinical and early development personnel, including through both separations and employee moves.  

The expansion includes new labs in Cambridge that it expects to open late this year. There will also be an interim facility in South San Francisco opening late this year, with about 100 scientists expected to be recruited there. Merck's looking for a long-term site in that area.

- read the blog post

Related Articles:
Merck tallies 36,000 job cuts in 5 years of restructuring
Merck job-cutting tensions displayed in public emails from Frazier, union rep

Read more on

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.